glp 1 agonist clinical trials Summaries of landmark with GLP-1 agonists GLP-1 Medications for Weight Loss:

Description

Both the American Diabetes Association (ADA) and the European Society of Cardiology (ESC) now advocate for GLP-1 receptor agonists in patients with atherosclerotic cardiovascular disease, regardless of their initial HbA1c levels

Though several molecules, such as mazdutide, a GLP/glucagon dual agonist, are being studied in various phases, the first agent targeting incretins other than just GLP-1 was approved in 2022 tirzepatide [41]

Molecular mechanisms underlying the impact of GLP-1RAs on cancer risk The regulation of cancer risk by GLP-1RAs involves several biological mechanisms, primarily encompassing metabolic regulation, direct anti-tumor effects, immune modulation, and epigenetic alterations

Department of Food and Agriculture (USDA)

JAMA Netw Open 3:e207419 Paccou J et al (2022) Bariatric surgery and skeletal health: a narrative review and position statement for management by the European calcified tissue society (ECTS)